Luisa Hector: Great. Thank you. So maybe my question would be on Beyfortus, just to get a bit more color on where you are with manufacturing and the ability to meet demand this year, and whether you would anticipate perhaps some demand for second season vaccination, and if — are you able to now show, given your sort of high vaccination rates in some countries, can you show that the emergency room, entry for the RSV has gone down? Like, do you have that sort of data to support the use of the vaccine? And that would be the first question. And then, obviously, I would like to, extend, thanks from everyone to JB, for all the conversations over the years. Thank you, JB. Congratulations on the move. And I guess the question for you would be, what words of advice you would pass on to better…
Paul Hudson: Well, thank you, Luisa. I think it’s very gracious of you to say that to JB. We’ll give him a moment or two to think about words of advice. Before that, Thomas, will come to you on Beyfortus. And perhaps if you’re open, you could share some of the data from Galicia as a guide to what it might look like. I know they’ve been publishing some of that, but on the supply for Beyfortus 2024?
Thomas Triomphe: Great point indeed. So as you’ve seen from the Q4 results, we are very happy with the strong Beyfortus launch in Q3 and Q4, with more than EUR400 million sales in Q4. I start by that because I think that’s showing that the implementation of all-infant protection program is highly feasible and goes very well with the record uptake in six months. Now back to your question, first on the supply element. As we discussed previously, clearly, Sanofi and AstraZeneca are working very hard to extend the manufacturing network, packaging sites, filling sites. And as always, and that’s why we’re not going to be very precise today, as always, first, you need to qualify the lines and then make them registered by the different regulatory authorities.
That’s the work that is ongoing right now in order to be able to completely, I would say, debottleneck the supply and have full supply for the season 2025. For the season 2024, we’ll see an increase in supply. And I think we can share here together, but our expectation is to reach blockbuster status for Beyfortus in 2024. To be more precise, it’s a bit early. Again, as we ramp up the supply progress and as we get further with regulatory authorities, we’ll come back to you. Your second point is extremely important, Luisa. I really thank you for asking that. Because at the end of the day, the reason why we are in this industry is to really make sure that we have an impact in terms of clinical efficacy, that actually babies don’t go to hospitalization or don’t go to ER.
I really ask everyone if you guys have a moment to look at the Galicia data, which is referenced on our slide there, Have a look there. I know very well that it’s not the end of the season, but the Spain data is very important because unlike the US or France, which have a partial patient coverage rate this year, the actual Spain data is in a country where there is about 90% coverage rate. And you will see that they show extremely impressive data, where they see that — where you can see that the hospitalization rate this year in babies less than eight months of age, i.e., eligible to Beyfortus, the hospitalization rate is extremely low. While for babies that are above one year of age, i.e., susceptible to normal RSV infection because they were not protected, actually it’s a high RSV season for them.
RSV disease is there. When you receive Beyfortus, it’s not there. You don’t go to hospitalization. We’ll provide you more data at the end of the season, obviously.
Paul Hudson: Second season?
Thomas Triomphe: Second season, the product is indicated for your first RSV season, except for a very small population of infants, either specific heart conditions or specific lung conditions, it’s usually depending on the population, but 1% of the newborn population, for which Beyfortus is [getting for the] (ph) second season. So it’s retargeting for the first season. But interestingly, as you have seen, we have an RSV toddler intranasal vaccine that we are targeting to bring just after Beyfortus, [indiscernible] available and protected.
Paul Hudson: Thank you, Thomas, and congrats again on an amazing launch. JB, you’ve had some time to reflect to what advice you were going to give. You’ve certainly given me plenty of advice while we’ve been together, so I’m sure you’re not short of something.
Jean-Baptiste de Chatillon: No, I’m not short. But first, thank you very much, Luisa. I’m a bit — it’s a lot of emotion for me today. And of course, the financials of the company are better, but what counts is that the pipeline on the science and innovation we have now, in our hands, where if I add the arrogance of an advice, it will be ready to make the most of it. Ready to make the most of it and bring them to fruition, develop them all in. That’s what we have decided. That’s what we should do. And of course, Paul, G&A as you know…
Paul Hudson: So [I just found the opening] (ph) comments, but I think we’ve all worked well as the management team, but JB and I particularly well. And we pushed each other pretty hard to be honest over the time. And it’s been necessary to try and have as much discipline as possible whilst making sure we take advantage of opportunities. I think your comment about pipeline is extraordinarily well made. We’ve made sacrifices to be in a position where we have it. Don’t squander it, I think is what you’re saying. And you’re right. I think for those, that should be interested, of course, we’d announced a cost saving program. I think you need to know that, aligned with JB’s wishes and comments, we go full ahead for the reallocation of that.
That doesn’t blink. And one of the reasons why I’m excited to work with Francois-Xavier is because he picks up this well run machine, but with the same intensity. And I think that’s very important for people to understand. We won’t squander it, JB. Okay, next question?
Eva Schaefer-Jansen: The next question is from Jo Walton, UBS. Joe? Joe, can you hear us? UBS team? Okay. Let’s move on and we’ll come back…
Jo Walton: Can you hear me?
Eva Schaefer-Jansen: Yes.
Jo Walton: I’m sorry. I have a question on the consumer side, please. Just looking at, any progress on the Rx-OTC switch trials that you’re doing for Tamiflu and Cialis? Just thinking as to whether they will — how visible they will be at the point of separation going forward? And, secondly, just on the timing of your COPD launch. I know that you’ve, filed and you don’t yet know the time frame of that review. Do you have a priority review voucher? Could we assume that you would use that for such an important launch? Many thanks.
Paul Hudson: Okay. Thanks, Jo. Great to be connected. So, Julie, updates on the switches?
Julie van Ongevalle: Sure. So, as you know, we have already launched Cialis together in the UK. And since our last call, we have now also received approval for Norway and Ireland. What — for the US, we have been conducting certain studies to support our strategy to [indiscernible]. Those studies are now complete, and we’re looking forward to discussing the results with the FDA over the coming quarter and hope to gain alignment with them on the next steps. And on Tamiflu, there is no update at this time.
Paul Hudson: Yeah. And I think, Julie, I mean, it is very much a conversation with the FDA, but I think it’s fair to say what was expected of us to be done, we’ve done. So now we find out whether it will be enough and that’s, we’ve gone further than others, but we’ll find out. So certainly progress on Cialis. I don’t know whether we want to go to Brian then next on COPD. There was a question about the voucher and assumptions around launch.
